Switch theme
Sign up to access all valuation multiples
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
2019
323
LTM Revenue n/a
LTM EBITDA n/a
$920M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BGM Group has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, BGM Group achieved revenue of $25.1M and an EBITDA of $0.9M.
BGM Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BGM Group valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $46.5M | $25.1M | XXX | XXX | XXX |
| Gross Profit | $6.2M | $1.8M | XXX | XXX | XXX |
| Gross Margin | 13% | 7% | XXX | XXX | XXX |
| EBITDA | -$1.3M | $0.9M | XXX | XXX | XXX |
| EBITDA Margin | -3% | 4% | XXX | XXX | XXX |
| Net Profit | $1.1M | -$7.8M | XXX | XXX | XXX |
| Net Margin | 2% | -31% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BGM Group's stock price is $10.
BGM Group has current market cap of $938M, and EV of $920M.
See BGM Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $920M | $938M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BGM Group has market cap of $938M and EV of $920M.
BGM Group's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate BGM Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BGM Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $920M | XXX | XXX | XXX |
| EV/Revenue | 36.7x | XXX | XXX | XXX |
| EV/EBITDA | 1045.7x | XXX | XXX | XXX |
| P/E | -650.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -271.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBGM Group's NTM/LTM revenue growth is n/a
BGM Group's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $14K for the same period.
Over next 12 months, BGM Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BGM Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BGM Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -46% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -169% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $14K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 18% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BGM Group acquired XXX companies to date.
Last acquisition by BGM Group was XXXXXXXX, XXXXX XXXXX XXXXXX . BGM Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BGM Group founded? | BGM Group was founded in 2019. |
| Where is BGM Group headquartered? | BGM Group is headquartered in United States of America. |
| How many employees does BGM Group have? | As of today, BGM Group has 323 employees. |
| Who is the CEO of BGM Group? | BGM Group's CEO is Mr. Chen Xin. |
| Is BGM Group publicy listed? | Yes, BGM Group is a public company listed on NAS. |
| What is the stock symbol of BGM Group? | BGM Group trades under BGM ticker. |
| When did BGM Group go public? | BGM Group went public in 2021. |
| Who are competitors of BGM Group? | Similar companies to BGM Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BGM Group? | BGM Group's current market cap is $938M |
| What is the current revenue growth of BGM Group? | BGM Group revenue growth between 2023 and 2024 was -46%. |
| Is BGM Group profitable? | Yes, BGM Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
